London Daily

Focus on the big picture.
Thursday, Jul 31, 2025

First pill to treat Covid gets approval in UK

First pill to treat Covid gets approval in UK

The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.

The tablet - molnupiravir - will be given twice a day to vulnerable patients recently diagnosed with the disease.

In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalisation or death by about half.

Health Secretary Sajid Javid said the treatment was a "gamechanger" for the most frail and immunosuppressed.

In a statement he said: "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid."

First oral treatment


Molnupiravir, developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics, is the first antiviral medication for Covid which can be taken as a pill rather than injected or given intravenously.

The UK has agreed to purchase 480,000 courses with the first deliveries expected in November.

Initially it will be given to both vaccinated and unvaccinated patients through a national study, with extra data on its effectiveness collected before any decision to order more.

The drug needs to be given within five days of symptoms developing to be most effective.

It's not immediately clear how it will be distributed so quickly by the NHS. It's thought some care homes may be offered supplies while other elderly or vulnerable patients may be prescribed it by their GP after testing positive for Covid.

Molnupiravir, developed by scientists at Ridgeback Biotherapeutics and MSD, is the first of a number of oral antiviral treatments for Covid to report clinical trial results.


The new treatment targets an enzyme that the virus uses to make copies of itself, introducing errors into its genetic code. That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.

Merck said that approach should make the treatment equally effective against new variants of the virus as it evolves in the future.

The UK regulator, the MHRA, said the tablet had been authorised for use in people who have mild to moderate Covid and at least one risk factor for developing severe illness such as obesity, old age, diabetes or heart disease.

The organisation's chief executive, June Raine, described it as "another therapeutic to add to our armoury against Covid-19".

"It is the world's first approved antiviral for this disease that can be taken by mouth rather than administered intravenously," she said.

"This is important, because it means it can be administered outside of a hospital setting, before Covid-19 has progressed to a severe stage."

England's deputy chief medical officer, Prof Jonathan Van-Tam, warned on Wednesday of some "hard months to come" in the pandemic.

He said that while Covid cases appeared to have stabilised, deaths were rising and there were signs infections were starting to "penetrate" older age groups.

The UK recorded 41,242 Covid cases on Thursday and 214 deaths within 28 days of a positive test.


Clinical trials


Earlier clinical trials of molnupiravir on 775 patients who had recently caught Covid found:

*  7.3% of those given the drug were hospitalised

*  that compares with 14.1% of patients who were given a placebo or dummy pill

*  there were no deaths in the molnupiravir group, but eight patients who were given a placebo in the trial later died of Covid

The results were published in a press release and have not yet been peer-reviewed.

But data suggest molnupiravir needs to be taken soon after symptoms develop to have an effect. An earlier study in patients who had already been hospitalised with severe Covid was halted after disappointing results.

In its approval document, the MHRA recommends the drug is used "as soon as possible" following a positive Covid test and within five days of symptoms onset.

Prof Penny Ward, from King's College London, who was not involved in the study, said: "If these outcomes are replicated in the UK population, then the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced.

"It seems likely that it will be restricted for use by those at highest risk of disease complications - for example older adults with heart, lung or kidney disease, diabetes or cancer."

The UK government has not disclosed how much its initial contract for 480,000 courses of molnupiravir is worth. But US authorities recently made an advance purchase of 1.7 million courses at a cost of roughly $1.2 billion, or $700 (£513) for each patient.

Other countries including Australia, Singapore and South Korea have also made purchase agreements.

Merck is the first company to report trial results of a pill to treat Covid, but other companies are working on similar treatments.

Its US rival Pfizer has started trials of two different antiviral tablets, while Swiss company Roche is working on a similar medication.

Comments

Oh ya 4 year ago
From what I have read they are trying to get people to think this is just a new ivermectin pill under a different name so it can still be patient thus making the maker lots of money. This is not the case, this is as bad for you as the jab is. Do not fall for the lie. The drug companies have no morals the new ad for jabbing 5 yr Olds proves that. Telling kids they will get super hero power if they take the jab just shows you the drug companies are run by the devil

Newsletter

Related Articles

0:00
0:00
Close
Former Judge Charged After Drunk Driving Crash Kills Comedian in Brazil
Jeff Bezos hasn’t paid a dollar in taxes for decades. He makes billions and pays $0 in taxes, LEGALLY
China Increases Use of Exit Bans Amid Rising U.S. Tensions
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Procter & Gamble to Raise U.S. Prices to Offset One‑Billion‑Dollar Tariff Cost
House Republicans Move to Defund OECD Over Global Tax Dispute
Botswana Seeks Controlling Stake in De Beers as Anglo American Prepares Exit
Trump Administration Proposes Repeal of Obama‑Era Endangerment Finding, Dismantling Regulatory Basis for CO₂ Emissions Limits
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
A family has been arrested in the UK for displaying the British flag
Mel Gibson refuses to work with Robert De Niro, saying, "Keep that woke clown away from me."
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
The British propaganda channel BBC News lies again.
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
×